EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudie

Trends in DMARD prescribing by rheumatologists, NPs, and PAs among medicare beneficiaries, 2013–2023: an observational retrospective cohort study

Roderick S Hooker, G Martin Reinhart

Rheumatology International · 23.06.2026 · 46 (7)

DOI: 10.1007/s00296-026-06203-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Rheumatology International, online erschienen am 23.06.2026. Verfasst von Roderick S Hooker und 1 weiteren Autor:innen. Beteiligte Einrichtung: , 15917 NE Union Rd, Ridgefield, WA, 98642, USA. Rodhooker6@gmail.com. Hauptthemen laut MEDLINE: Antirheumatic Agents, Practice Patterns, Physicians', Rheumatologists, Nurse Practitioners. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To understand the roles of physician associates [PAs] and nurse practitioners [NPs] in rheumatology care delivery, we examined the pharmacoepidemiology of disease-modifying antirheumatic drug [DMARD] prescriptions among Medicare beneficiaries. The intent was to inform regulatory decisions, optimize prescribing, and better manage risk in older populations. An observational, retrospective cohort study of Medicare Part D claims from 2013 to 2023 compared rheumatologist prescribers with primary care providers (family practice [FP] and internal medicine [IM]) and with PAs and NPs. Trends in DMARD prescriptions and prescriber counts were reported as absolute numbers and percentages and presented graphically. Over the 10-year period from 2013 to 2023, 13 of the most commonly prescribed DMARDs in Medicare Part D claims were tracked. Methotrexate was the most frequently prescribed, followed by hydroxychloroquine. The share of DMARD claims by rheumatologists remained relatively steady (58-60%) during this period, whereas the shares for PAs and NPs increased. Expressed as unique prescriber counts, the trends are even stronger: in 2013, NPs and PAs represented 6.7% and 4.2% of DMARD prescribers, respectively, increasing to 19.2% and 8.9% by 2023, while the percentages of IM and FP physicians declined from 45.7% to 35.8% to 32.7% and 30.0%, respectively, during this same period. DMARD prescriptions for the Medicare population increased from 2013 to 2023, with NPs and PAs assuming a growing role in prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsPractice Patterns, Physicians'RheumatologistsNurse PractitionersHumansUnited StatesRetrospective StudiesMedicare Part DFemaleAgedMaleDrug Prescriptions

Stichwörter der Autor:innen

Antirheumatic agentsMedicare part DNurse practitionersPharmacoepidemiologyPhysician assistantsRheumatoid arthritis

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • , 15917 NE Union Rd, Ridgefield, WA, 98642, USA. Rodhooker6@gmail.com.
  • , 11187 SE Stark St., Portland, OR, 97216, USA.

Zitieren

APA

Hooker, R. S., & Reinhart, G. M. (2026). Trends in DMARD prescribing by rheumatologists, NPs, and PAs among medicare beneficiaries, 2013–2023: an observational retrospective cohort study. Rheumatology International, 46(7). https://doi.org/10.1007/s00296-026-06203-3

Vancouver

Hooker RS, Reinhart GM. Trends in DMARD prescribing by rheumatologists, NPs, and PAs among medicare beneficiaries, 2013–2023: an observational retrospective cohort study. Rheumatology International. 2026;46(7). doi:10.1007/s00296-026-06203-3

BibTeX
@article{Hooker2026,
  author = {Hooker, Roderick S and Reinhart, G Martin},
  title = {Trends in DMARD prescribing by rheumatologists, NPs, and PAs among medicare beneficiaries, 2013–2023: an observational retrospective cohort study},
  journal = {Rheumatology International},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1007/s00296-026-06203-3}
}
Kostenlos starten →